Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

A Phase 1b, Randomized, Subject And Investigator-Blinded, Sponsor-Open, Placebo Controlled, Cross-Over Efficacy, Safety And Tolerability Study Of Single Oral Split Dose Administration Of PF-06412562 In Subjects With Parkinson's Disease

The B7441003 study will assess PF-06412562 for motor benefit in Parkinson's disease subjects. Safety, tolerability and PK of PF-06412562 in Parkinson's disease subjects will also be evaluated.

Inclusion Criteria:

• Male or female subjects with a diagnosis of idiopathic Parkinson's disease.
• Daily L-dopa dose between 300 and 1200 mg.
• MBRS score >1.

Exclusion Criteria:

• Surgical intervention for Parkinson's disease.
• History of troublesome dyskinesias.
• Any significant AXIS I psychiatric disease.